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Introduction
On average, about 1 in 40 people of Ashkenazi Jewish
descent carry a copy of one of the ancestral mutations
185delAG and 5382insC in BRCA1 and 6174delT in
BRCA2 [1]. Female carriers have a high lifetime risk of
breast cancer estimated to be in the range of 30–60%,
and about a 20% lifetime risk of ovarian cancer [1,2]. The
increased risk of breast cancer depends on age, and
perhaps gene [2], and is between 3-fold and 20-fold. In
theory about 20% of all breast cancers in Ashkenazi
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Abstract
Introduction: Ancestral mutations in BRCA1 and BRCA2 are
common in people of Ashkenazi Jewish descent and are
associated with a substantially increased risk of breast and
ovarian cancer. Women considering mutation testing usually
have several personal and family cancer characteristics, so
predicting mutation status from one factor alone could be
misleading. The aim of this study was to develop a simple
algorithm to estimate the probability that an Ashkenazi Jewish
woman carries an ancestral mutation, based on multiple
predictive factors.
Methods: We studied Ashkenazi Jewish women with a
personal or family history of breast or ovarian cancer and living
in Melbourne or Sydney, Australia, or with a previous diagnosis
of breast or ovarian cancer and living in the UK. DNA samples
were tested for the germline mutations 185delAG and
5382insC in BRCA1, and 6174delT in BRCA2. Logistic
regression was used to identify, and to estimate the predictive
strength of, major determinants.
Results: A mutation was detected in 64 of 424 women. An
algorithm was developed by combining our findings with those
from similar analyses of a large study of unaffected Jewish
women in Washington. Starting with a baseline score, a multiple
of 0.5 (based on the logistic regression estimates) is added for
each predictive feature. The sum is the estimated log odds ratio
that a woman is a carrier, and is converted to a probability by
using a table. There was good internal consistency.
Conclusions: This simple algorithm might be useful in the
clinical and genetic counselling setting. Comparison and
validation in other settings should be sought.
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Jewish women would be attributable to these mutations,
so it is important to be able to identify the women most
likely to carry this high genetic cancer risk.
Previous studies, typically of clinic-based samples, have
identified several factors that individually predict a woman’s
mutation status. Personal factors include a previous history
of breast or ovarian cancer, especially if breast cancer was
diagnosed at a relatively early age, and bilateral disease or
both cancers in the same woman [3–10]. The occurrence
of these factors in close relatives has also been found in
general to be predictive, but the strength of prediction is
weaker and the conclusions are less definitive.
The aim of this paper was to try to develop a simple yet
reliable model for estimating the probability that an Ashke-
nazi Jewish woman carries a copy of one of the ancestral
mutations in BRCA1 or BRCA2 that will be applicable
across the full spectrum of personal and family history.
Note that unless the data used to derive such a model
come from a random population sample, and for the
Ashkenazim this is difficult to achieve, any prediction of
the absolute probability of being a carrier cannot be accu-
rate unless it takes into account all predictive features.
This is because individuals concerned about their muta-
tion status often have multiple predictive features. Predic-
tions based on a consideration of one factor alone could
be misleading.
Previous logistic regression analyses
A few studies have considered multiple predictive factors
together in developing a predictive statistical model, and
included Ashkenazi women [3,11–15]. The largest was of
more than 5000 volunteer men and women of Ashkenazi
Jewish descent living in Washington [3]. As a conse-
quence of the sampling strategy of that study, which was
designed to give population-based estimates of the cancer
risks in mutation carriers, the great majority of participants
had no personal or family history of breast or ovarian
cancer. There were few women with the rare predictive fea-
tures, especially among those who were affected.
Logistic regression models were fitted to data from the
Washington study published in tabular form [13,16], and
estimated the predictive strength of some characteristics
of family breast cancer history while adjusting for age at
diagnosis in women with breast or ovarian cancer or age
at testing in unaffected women. For women with a previ-
ous diagnosis of breast cancer, the probability of being a
carrier decreased successively as the age at diagnosis
increased from under 40 years to 40–49 years to
50–59 years to 60 years and over. The log (to the base e)
odds decreased by about 1 unit (log odds = 0.97; odds
ratio = 2.6) per age group. For women with no previous
diagnosis of breast or ovarian cancer, the probability of
being a carrier decreased successively as the age at
testing increased from under 40 years to 40–49 years to
50–59 years to 60 years and over. This time the log odds
decreased by about 0.5 unit (log odds = 0.43; odds
ratio = 1.5) per age group.
An important point revealed by this modelling was that, on
the logistic scale, the effects associated with breast
cancer in first-degree relatives seemed to be independent
of the disease status of the tested individual [13,16]. We
shall exploit this feature in our LAMBDA model below.
Each affected first-degree relative increased the log odds
of being a carrier by about 1 unit (log odds = 0.99; odds
ratio = 2.7). Similarly, the log odds of being a carrier
increased by about 1.5 units (log odds = 1.49; odds
ratio = 4.4) if any first-degree relative had been diagnosed
before 50 years of age. Similar estimates were reported by
a Canadian study [10]. The Washington data were not
presented in a form that allowed concurrent modelling of
the effects of both the number of affected relatives and
the presence of early age at diagnosis in a relative. For
ovarian cancer, having a first-degree relative with that
disease increased the log odds of being a carrier by about
1.5 units (log odds = 1.41; odds ratio = 4.1) [13].
A similar logistic regression analysis was conducted of
data on 171 Ashkenazi Jewish women living in the UK
who had a previous diagnosis of breast cancer [14]. In the
present paper the data used in that UK analysis, including
13 women who had a previous diagnosis of ovarian
cancer only, are combined with data from Ashkenazi
Jewish women living in Australia who have either a per-
sonal history or a family history of breast or ovarian cancer.
The features that are most predictive of mutation status
when all are considered together have been identified, and
the extent to which each feature is predictive of mutation
status have been quantified.
We also compared and combined parameter estimates
from our new analyses with those from our logistic regres-
sion analyses of data on unaffected women from the
Washington study [13], and derived a simple algorithm to
estimate the probability that an Ashkenazi Jewish woman
carries one of the three ancestral mutations in BRCA1
and BRCA2. The algorithm therefore applies to women
with or without a personal history of breast or ovarian
cancer. The method of calculating the probability is
straightforward: each predictive feature has an associated
score, and the sum of these scores is converted to a prob-
ability by reference to a table. It should therefore be useful
to a broad range of health professionals.
Methods
Ethical approval
The study was approved in Australia by the Human
Research Ethics Committees of the Peter MacCallum
Cancer Institute (Melbourne), The Prince of Wales Hospital
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(Sydney) and The University of Melbourne, and in the UK
by the Local Research Ethics Committee at Guy’s and St
Thomas’ Trust.
Subjects
In Australia, eligible women were self-identified as being of
Ashkenazi Jewish descent, living in Melbourne or Sydney,
who had reported either having had a previous diagnosis
of breast or ovarian cancer themselves, or having a first-
degree or second-degree relative who had been diag-
nosed with breast or ovarian cancer. They were recruited
between 1996 and 2000 through announcements in the
media (local Jewish newspapers, 32%; other newspapers,
3%), approaches including brochures to general practi-
tioners, gynaecologists, breast surgeons and oncologists
(19%), the family cancer genetics clinics associated with
this study (9%), information evenings (11%), and friends
or relatives (26%).
In the UK, eligible women were self-identified as being of
Ashkenazi Jewish descent and had a previous diagnosis of
breast or ovarian cancer. Recruitment was through clini-
cians and Jewish agencies, lectures, broadcasts and
newspaper articles [14].
For the purposes of the analyses below, the first woman in
a family recruited was nominated as the proband. In Aus-
tralia there were 240 probands, of whom 148 had no pre-
vious diagnosis of breast or ovarian cancer, 81 had breast
cancer only, 9 had ovarian cancer only, and 2 had both
breast and ovarian cancer. In UK there were 184
probands, of whom 169 had breast cancer, 13 had
ovarian cancer, and 2 had both breast and ovarian cancer.
Information on personal and family cancer history
Participants in Australia were administered, face to face,
the structured questionnaire developed by the Coopera-
tive Family Registry for Breast Cancer Studies [17]. This
instrument asked about past cancer history and Ashkenazi
Jewish descent. Personal and family cancer histories were
self-reported and not confirmed. Family history was
recorded by first identifying all first-degree and second-
degree adult relatives, and then asking for each about any
cancer history.
Participants in the UK gave a similarly detailed family
history to at least second-degree relatives, and information
was collected on all cancer cases. Breast and ovarian
cancer in the proband was confirmed through the relevant
clinician, but no confirmation was attempted for reports in
other family members [14].
Mutation testing
Blood samples were collected from all probands. In Aus-
tralia, exons 2 and 20 of BRCA1 and a fragment of exon
11 of BRCA2 were amplified and manually sequenced.
These regions encompassed the mutations 185delAG
and 5382insC in BRCA1 and 6174delT in BRCA2 [18].
In the UK, a heteroduplex assay was used to screen for
the three ancestral mutations, as described by Hodgson
and colleagues [14].
Statistical methods
Unconditional multiple linear logistic regression was used
to model the probability that the proband was a mutation
carrier (in other words that she carried a copy of one of
the three specific mutations) as a function of her personal
and family history, and either age at diagnosis of first
cancer if the index person had a previous diagnosis of
breast or ovarian cancer, or age at testing if unaffected
(that is, not reporting a prior diagnosis of breast or ovarian
cancer). The model was a linear function of the logit of the
probability; ie log (p/[1-p]) =β0 +β1x1 +β2x2 +β3x3 + …,
where log signifies logarithm to the base e, p is the proba-
bility, and for each i = 1, 2, 3… each xi represents a poten-
tially predictive factor that can either take two values (0 if
absent or 1 if present) or is a number of affected relatives
(0, 1, 2, …), and βi is the corresponding logistic regres-
sion coefficient. Therefore exp(βi) is the ratio of the odds
for being a mutation carrier comparing a woman with the
ith characteristic with one without that characteristic, or
having one more affected relative, given that the two
women are the same for all other characteristics. If p is
small, exp(βi) is approximately the relative risk of being a
carrier associated with factor i. Logistic regression analy-
ses were conducted with the software package GLIM
[19]. Model selection was based on forwards selection
and confirmed by backwards elimination, with the fits of
nested models compared by the likelihood ratio test based
on asymptotic likelihood theory. Tests for interaction terms
were also performed. Following convention, all nominal
P values were two-tailed. In general, proportions were
compared with Pearson χ2-test statistics, or Fisher’s exact
test for small cells. During modelling, trends in proportions
across groups were assessed by linear logistic regression
by fitting single parameters to represent linear effects (on
the logit scale) with the underlying variable considered as
a continuum.
Characteristics specific to the probands were having a
previous diagnosis of primary breast cancer or of ovarian
cancer, and of having bilateral breast cancer. To be con-
sistent with the presentation of the Washington study [3],
age at diagnosis for affected women, and age at testing
for unaffected women, were both categorised as under
40 years, 40–49 years, 50–59 years, or 60 years and over
(and classified as 1–4 for the assessment of trends).
These age groupings were also applied to the age at
onset of cancers in relatives. Family histories were cate-
gorised according to the number of affected first-degree
relatives (mothers, sisters and daughters), and the number
of affected second-degree relatives (maternal and paternal
grandmothers and aunts, nieces, granddaughters and half-
sisters), separately for breast cancers and ovarian
cancers. Bilateral breast cancer in any first-degree or
second-degree relative was also included. The develop-
ment of the LAMBDA model with the use of the results of
the logistic regression analyses of our data and the Wash-
ington study data is described in detail in the Results
section.
The internal goodness of fit of the LAMBDA model was
assessed several ways, as described by Cox and Snell
[20]. For each woman, let λi be her LAMBDA score and
pi the corresponding predicted probability. First, the
observed proportions of carriers in various categories of
pi were compared with the expected proportions by using
standard contingency table methods with the Pearson χ2
test statistic. Second, the expected total number of carri-
ers predicted by the model was calculated by summing
over the predicted probabilities (that is, E0 =∑pi). This
was compared with the observed number of carriers, O0,
by calculating the statistic Z0 = (O0 – E0)/[var(E0)]1/2,
where var(E0) =∑pi(1 – pi), which has a standard normal
distribution under the null hypothesis of no bias. Devia-
tions test whether the predicted values were systemati-
cally too high or too low. Third, we let Yi = log(2pi) if the
ith woman was a carrier and log[2(1 – pi)] otherwise,
E1 =n log2+∑pi log(pi)+∑(1–pi) log(1–pi) and O1 = ∑Yi.
The statistic Z1 = (O1 – E1)/[var(E1)]1/2, where var(E1) =
∑pi(1 – pi){log[pi/(1 – pi)]}2 has a standard normal distrib-
ution under the null hypothesis, and deviations test
whether the predicted values were too clustered or too
dispersed.
Results
Descriptive statistics for the Australian and UK data
Of the 424 probands, 64 (15%) had a germline ancestral
mutation; 26 had 185delAG and 10 had 5382insC in
BRCA1, whereas 28 had 6174delT in BRCA2. Table 1
shows that there were 148 probands with no previous
history of breast or ovarian cancer (median age 44 years).
Of the remainder, 250 had breast cancer only, 22 had
ovarian cancer only, and 4 had both breast and ovarian
cancer. The median ages at diagnosis of these three
groups were 49, 44 and 59 years, respectively.
Tables 2 and 3 show that, of the probands with no previ-
ous diagnosis of breast or ovarian cancer, 68% had at
least one first-degree relative and 48% at least one
second-degree relative with breast cancer, and 12% had
at least one first-degree relative with ovarian cancer. Of
the probands with a previous diagnosis of breast and/or
ovarian cancer, the percentages with the above family his-
tories were 29% and 34% for breast cancer and 7% for
ovarian cancer, respectively. That is, as a consequence of
the design, a smaller proportion of the probands with
breast and/or ovarian cancer had these family history cate-
gories than that of the probands with no previous diagno-
sis (P = 0.001, 0.004 and 0.04, respectively). The crude
mutation frequencies presented here and below must
therefore be interpreted with care, taking into account the
existence and differing extents of family history that we are
referring to, as well as the ‘age at testing’ in unaffected
women and the ‘age at diagnosis’ in affected women.
Table 1 shows that the proportion of mutation carriers dif-
fered by the proband’s cancer status, increasing from 8%
in those with no previous diagnosis of breast or ovarian
cancer to 17% in those with breast cancer only, to 32% in
those with ovarian cancer, and to 75% in those four with
both breast and ovarian cancer (P = 0.004). Table 1 also
shows that, in probands with a previous diagnosis of
breast cancer, there was a strong negative effect of age at
diagnosis: the proportion of carriers went from 38% for
40 years or younger, to 21% for 40–49 years, to 7% for
50 years or older (P = 0.0001). In probands with ovarian
cancer, however, no effect of age at diagnosis on mutation
status was observed (P = 0.09), although it should be
noted that no carriers were observed among the eight
ovarian cancer cases diagnosed before the age of
50 years. For unaffected probands, Table 1 shows that the
proportion of mutation carriers was 12% in those under
40 years compared with 6% in those 40 years or older
(P = 0.25).
Table 2 shows that the proportion of mutation carriers
generally increased as the number of first-degree relatives
with breast cancer increased. For example, in probands
with a previous diagnosis of breast cancer, it increased
from 13% to 24% to 44% as the number increased from
zero to one to two or more (P = 0.004), whereas in
probands with no previous diagnosis of breast or ovarian
cancer it increased from 2% to 11% as the number
increased from zero to one or more (P = 0.06). It also
shows that the proportion was relatively stable according
to the number of second-degree relatives with breast
cancer. In probands with a previous diagnosis it
decreased from 18% to 14% as the number increased
from zero to one or more, whereas in those with no previ-
ous diagnosis it increased from 7% to 8%, respectively.
Table 3 shows that the proportion of mutation carriers was
generally greater if the proband had a family history of
ovarian cancer, irrespective of whether it was in a first-
degree or a second-degree relative. In probands with
breast cancer only, it was 13% in those with no family
history, compared with 32% in those with a first-degree or
second-degree relative with ovarian cancer (P = 0.002).
Given that age at diagnosis in probands with breast
cancer was predictive of mutation status, it is logical also
to examine age at diagnosis of breast cancer in affected
relatives. Table 4 shows that in unaffected probands
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(overall proportion of carriers 8%), the proportion of muta-
tion carriers decreased with age at diagnosis of breast
cancer in a first-degree relative from 20% if diagnosed
before age 40, to 9% if diagnosed at a later age; however,
the difference was not significant (P = 0.4). For second-
degree relatives, these proportions were 17% and 7%,
respectively (P = 0.4). In probands with breast cancer only
(overall proportion of carriers 17%), these proportions
were 50%, 30%, 33% and 17% for any first-degree rela-
tive diagnosed before 40, 40–49, 50–59 and 60 or more
years, respectively (P for trend = 0.09), and 38%, 25%,
13% and 10% for any second-degree relative diagnosed
Breast Cancer Research    Vol 5 No 6 Apicella et al.
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Table 1
Proportions of probands with a germline ancestral mutation in BRCA1 or BRCA2 out of total tested (percentages in parentheses),
by personal cancer history and age at testing in unaffected women, or age at first diagnosis in affected women
Age group*
Median
Cancer status Under 40 years 40–49 years 50–59 years 60 years or older Total age (years)
No breast or ovarian cancer 6/50 (12%) 3/48 (6%) 2/33 (6%) 1/17 (6%) 12/148 (8%) 44
Breast cancer only 15/40 (38%) 19/89 (21%) 4/68 (6%) 4/53 (8%) 42/250 (17%) 49
Ovarian cancer only 0/8 (0%) 3/6 (50%) 2/5 (40%) 2/3 (67%) 7/22 (32%) 44
Breast and ovarian cancer 0/0 (–) 1/1 (100%) 1/1 (100%) 1/2 (50%) 3/4 (75%) 59
Total 21/98 (21%) 26/144 (18%) 9/107 (8%) 8/75 (11%) 64/424 (15%)
*Age at testing for unaffected women, age at diagnosis in affected women
Table 2
Proportions of probands with a germline ancestral mutation in BRCA1 or BRCA2 out of total tested (percentages in parentheses),
by personal cancer history and number of first-degree relatives with breast cancer, and number of second-degree relatives with
breast cancer
No. of first-degree relatives with breast cancer No. of second-degree relatives with breast cancer
Cancer status 0 1 2 3 0 1 2 3 4 5
No breast or 1/47 11/94 0/7 – 6/77 5/56 1/14 ) 0/1 – –
ovarian cancer (2%) (12%) (0%) (7%) (9%) (7% (0%)
Breast cancer only 22/175 16/66 4/8 0/1 30/165 9/64 1/15 1/5 – 1/1 
(13%) (24%) (50%) (0%) (18%) (14%) (7%) (20%) (100%) 
Ovarian cancer only 6/17 1/5 – – 5/17 2/4 – – 0/1 –
(35%) (20%) (29%) (50%) (0%)
Breast and 2/3 1/1 – – 1/1 2/3 – – – –
ovarian cancer (67%) (100%) (100%) (67%)
Table 3
Proportions of probands with a germline ancestral mutation in BRCA1 or BRCA2 out of total tested (percentages in parentheses),
by personal cancer history and number of first-degree relatives with ovarian cancer, and with number of second-degree relatives
with ovarian cancer
No. of first-degree relatives with ovarian cancer No. of second-degree relatives with ovarian cancer
Cancer status 0 1 2 0 1 2
No breast or ovarian cancer 10/131 (8%) 8/89 (9%) 0/7 (0%) 11/144 (8%) 1/4 (25%) –
Breast cancer only 34/237 (14%) 13/42 (31%) – 38/242 (16%) 4/5 (80%) 0/3 (0%)
Ovarian cancer only 4/18 (22%) 3/4 (75%) – 5/20 (25%) 2/2 (100%) –
Breast and ovarian cancer 3/3 (100%) 0/1 (0%) – 3/4 (75%) – –
in the same age groups (P for trend = 0.03). There were
too few probands with ovarian cancer to identify any influ-
ence of age at diagnosis of breast cancer in their relatives.
For ovarian cancer in relatives, there was no evidence that
the age at diagnosis influenced mutation status (data not
shown).
Of probands with bilateral breast cancer, 34% (10 of 29)
had a mutation, in comparison with 14% of those with uni-
lateral breast cancer only (P = 0.01). Of probands who
had a first-degree or second-degree relative with bilateral
breast cancer, 24% (7 of 29) had a mutation, in compari-
son with 14% of those who did not have a first-degree or
second-degree relative with bilateral breast cancer
(P = 0.2).
Logistic regression analyses of the combined
Australian and UK data
Given the possible confounding between the potential
predictors of mutation status identified above, it is essen-
tial that statements about the absolute and relative proba-
bilities – and therefore the predictive effects of factors –
be based on an analysis that takes into account all factors
simultaneously. Table 5 shows the parameter estimates
and standard errors from a multiple linear logistic regres-
sion analysis of a model that included all the listed vari-
ables. It shows that, on the log odds scale, the strongest
predictors of mutation status were breast cancer in the
proband if age at diagnosis was under 50 years
(P < 0.002), breast cancer in a first-degree relative if age
at diagnosis was under 60 years (P < 0.003), and irre-
spective of age at diagnosis, ovarian cancer in the
proband (P = 0.0001), in a first-degree relative
(P = 0.003), or in a second-degree relative (P = 0.04).
There was marginal evidence of an additional strong effect
of a bilateral breast cancer at any age (P = 0.07). All these
factors would more than double the odds of being a muta-
tion carrier. The effects of breast cancer in the proband
diagnosed when aged 50–59 years, and when 60 years or
older, were more modest but imprecise (P = 0.4 and 0.3,
respectively), and there was marginal evidence of breast
cancer diagnosed in a second-degree relative before the
age of 40 years (P = 0.13). No evidence was found for an
independent effect of breast cancer in a first-degree rela-
tive diagnosed after the age of 60 years (P = 0.9), or of
bilateral breast cancer at any age in a relative (P = 0.9).
When the latter two effects were removed from the model
displayed in Table 5, the estimates and standard errors of
the remaining factors were virtually unchanged. There was
also no evidence of interaction effects, on the logit scale,
between the factors listed in Table 5. Furthermore, there
was no evidence that the estimates differed by country
(UK versus Australia).
There was marginal evidence within this data set for a
negative effect of age at testing in probands without a pre-
vious diagnosis of breast or ovarian cancer. However,
almost all had a family history of breast or ovarian cancer,
and after allowing for these factors the effect of age at
testing was no longer nominally significant.
The probability that a proband with a given set of personal
and family characteristics is a mutation carrier can be esti-
mated from the model fit shown in Table 5. Start with a log
odds score of θ= the baseline coefficient, –3.767. For
each personal characteristic of the proband, add the
respective regression coefficient to θ. For each family
history characteristic, multiply the respective coefficient by
the number of affected relatives and add that to θ. The
final cumulative log odds score, θ, is equivalent to the
probability exp(θ)/[1 + exp(θ)].
Development of the LAMBDA model
Our aim was to develop a simple model for predicting
whether or not an Ashkenazi woman had a germline muta-
tion. Analyses of the Washington data [13,16] have
shown that, when modelled on the log odds scale, the
effects of family history were independent of the
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Table 4
Proportions of probands with a germline ancestral mutation in BRCA1 or BRCA2 out of total tested (percentages in parentheses),
by personal cancer history and having a relative with breast cancer with given age at diagnosis, for first-degree relatives and for
second-degree relatives
Age at diagnosis for first-degree Age at diagnosis for second-degree
relatives with breast cancer relatives with breast cancer
40–49 50–59 60 years 40–49 50–59 60 years
Cancer status <40 years years years or older <40 years years years or older
No breast or ovarian cancer 3/15 (20%) 4/29 (14%) 4/34 (12%) 0/28 (0%) 1/6 (17%) 2/23 (9%) 2/19 (11%) 1/32 (3%)
Breast cancer only 3/6 (50%) 7/23 (30%) 7/21 (33%) 5/30 (17%) 3/8 (38%) 4/16 (25%) 3/24 (13%) 5/52 (10%)
Ovarian cancer only 1/1 (100%) 0/1 (0%) 0/1 (0%) 0/2 (0%) 0/0 (–) 0/2 (0%) 2/2 (100%) 1/3 (33%)
Breast and ovarian cancer 0/0 (–) – 1/1 (100%) – – – – –
proband’s cancer status. Furthermore, as noted in the
Introduction, the absolute magnitudes of the effects of age
at diagnosis of breast cancer in the proband, and of early
diagnosis of breast cancer in a first-degree relative, had a
log odds ratio of about 1.0, whereas for age at testing in
unaffected probands the absolute effects were about 0.5.
We therefore tried to simplify the logistic regression model
fit shown in Table 5, and combine information from the
Washington study analyses, to produce a model for the
Log odds of the probability of carrying an Ancestral Muta-
tion in BRCA1 or BRCA2 for a Defined personal and
family cancer history in an Ashkenazi Jewish woman,
called LAMBDA and represented by the symbol λ. The
resulting model is shown in Figure 1. The total LAMBDA
score is calculated on the log odds scale and is converted
to a probability by the formula exp(λ)/[1 + exp(λ)]. This is
easily done with the LAMBDA conversion table at the
bottom of Figure 1, given that only multiples of 0.25 are
valid scores for λ.
For an affected proband, the effect of each age group at
diagnosis of breast cancer is 1 unit, which is consistent
with the Washington study and our findings for age
groups under 50 years. The effect of diagnosis of ovarian
cancer is 3 units. The additional effect of a bilateral breast
cancer is 1 unit (see Table 5). Note that if a woman has
had both breast and ovarian cancer, her λ score will be
that due to her breast cancer, and decided by the age at
diagnosis, plus 3 for the diagnosis of ovarian cancer.
Our study was of women with a personal or family history
of breast or ovarian cancer; it was therefore limited in
making any inference about unaffected women. For
example, the effectively null result for age at testing might
be a consequence of limited power. In contrast, the
Washington study contained 3419 unaffected women,
80% without a family history [3]. It found a decrease in log
odds ratio of about 0.5 for each successive decade [13],
so this was built into the LAMBDA model.
The effect for each cancer in a first-degree relative has
been taken to be one-half that of the same condition in the
proband herself, which is generally consistent with Table 2
except for breast cancer at older ages. A term has been
included for each breast cancer in a second-degree rela-
tive, provided that it was diagnosed before the age of
40 years, given the strong effect of this characteristic in
probands and first-degree relatives and the marginal evi-
dence of such an effect in Table 2. A term for each ovarian
cancer in a second-degree relative has also been
included, given the evidence in Table 3.
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Table 5
Logistic regression coefficients (β), standard errors and nominal significance levels for potentially predictive factors for an
Ashkenazi Jewish woman having an ancestral mutation in BRCA1 or BRCA2, derived from multiple linear logistic regression
Characteristic β Standard error P
Baseline –3.767 0.436 0.001
Proband breast cancer diagnosis <40 years 2.570 0.523 0.0001
Proband breast cancer diagnosis 40–49 years 1.707 0.455 0.0002
Proband breast cancer diagnosis 50–59 years 0.493 0.602 0.4
Proband breast cancer diagnosis 60+ years 0.578 0.598 0.3
Proband bilateral breast cancer at any age 0.912 0.500 0.07
Proband ovarian cancer at any age 2.621 0.570 0.0001
For each relative with cancer
1st degree, breast cancer diagnosis <40 years 1.790 0.637 0.005
1st degree, breast cancer diagnosis 40–49 years 1.154 0.438 0.008
1st degree, breast cancer diagnosis 50–59 years 1.227 0.419 0.003
1st degree, breast cancer diagnosis 60+ years 0.033 0.482 0.9
1st degree, ovarian cancer at any age 1.339 0.454 0.003
2nd degree, breast cancer diagnosis <40 years 0.892 0.591 0.13
2nd degree, ovarian cancer at any age 1.004 0.489 0.04
1st or 2nd degree, bilateral breast cancer at any age –0.088 0.572 0.9
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Figure 1
Estimation of the probability that an Ashkenazi Jewish woman carries an ancestral mutation in BRCA1 or BRCA2 based on her personal and family
history of breast or ovarian cancer.
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coefficient by the number of affected relatives with that feature, and then write this in the shaded box alongside.
Add all the scores to obtain LAMBDA, then use the LAMBDA CONVERSION TABLE to give the estimated  PROBABILITY
that an Ashkenazi Jewish woman carries an ancestral mutation in BRCA1 or BRCA2.
Tests of internal consistency of the LAMBDA model
Table 6 shows that, on the basis of each woman’s pre-
dicted λ score, there were an expected 66.2 carriers in
comparison with the observed 64, giving no evidence for a
systematic bias (Z0 = –0.35, p = 0.3). It also shows that
the expected and observed numbers of carriers were in
good agreement, especially in women with a 50% or
greater predicted probability of being a carrier. There was
no evidence of a deviation greater than expected by
chance (χ52 = 10.0, p = 0.07). There was no evidence that
the predicted scores were too clustered or too dispersed
(Z1 = –1.26, p = 0.2).
Discussion
We have attempted to create a simple algorithm that can
be used easily in the clinical setting to predict the proba-
bility that an Ashkenazi Jewish women has inherited a high
and detectable genetic risk of breast and ovarian cancer.
We have used logistic regression, and being aware of the
usual potential problems raised by Wacholder and Hartge
[21], have carefully considered the dose relationships
starting with detailed descriptive analyses. We have
addressed internal consistency (given that the LAMBDA
model was in part developed from our data) and did not
find any evidence of systematic bias or under-dispersion
or over-dispersion. In developing the LAMBDA model we
have considered those personal and family cancer history
features that have been reported to influence the probabil-
ity of being a mutation carrier when considered on their
own. Given that women considering genetic testing often
have two or more such factors, it is important that a multi-
variate model be used for predicting mutation status, as
we have done here.
We have relied not only on our own analyses, which pro-
vided the framework for modelling the effects of a previous
diagnosis of breast or ovarian cancer and the effects of
various extents of family histories, but also on the large
Washington study in which the vast majority of women
were unaffected and did not have a family history, or at
most a modest family history. In other words, that data set
complements ours, and the LAMBDA model has inte-
grated the two so as to provide valid estimates for women
across a range of personal and family cancer histories.
Here we have taken an empirical approach to estimating a
woman’s mutation status. Another way is to specify a
mathematical model and use a conditional likelihood
approach, such as that used by Parmigiani and colleagues
to develop BRCAPRO [22]. However, that model was
based on the assumption that mutations in BRCA1 or
BRCA2 account for all the aggregation of breast cancer in
the family under consideration, and this is not true even in
the current setting. Epidemiological studies involving
mutation testing of cases unselected for their family
history are showing that perhaps less than 20% of familial
aggregation on a population basis can be attributed to
deleterious mutations in these two genes [23]. It is impor-
tant that such approaches build into their models other
familial factors, such as other major genes and/or poly-
genic effects [24,25].
We have used individual characteristics in our model.
Other empirical models have been proposed, but they
have tended to use the broad family characteristics, such
as the number of affected relatives or their average age at
onset [11,12]. It is not clear what was meant by ‘family’ in
the data sets used to derive those models, and given that
families vary in their size and extent, this might be problem-
atic in using those models in other settings. Furthermore,
none of those models were based on substantial numbers
of Ashkenazi Jewish women.
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Table 6
Observed and expected numbers of mutation carriers, as predicted by the LAMBDA model, for categories based on predicted
range of probability of being a carrier
Predicted range Numbers of carriers (percentage)
λ Probability (%) Number of women Observed Expected
<–3.5 <2 128 5 (4%) 2.1 (2%)
–3.5 to –2.25 2–10 117 12 (10%) 7.2 (6%)
–2.0 to –1.25 10–25 84 11 (13%) 13.4 (16%)
–1.0 to –0.25 25–50 59 14 (24%) 20.1 (34%)
0.0 to 0.75 50–75 30 16 (53%) 18.2 (61%)
≥1.0 ≥75 6 6 (100%) 5.1 (85%)
Total 424 64 (15%) 66.2 (16%)
We have pooled the three ancestral mutations in our
analyses, because if a woman has a sufficiently high prob-
ability of being a carrier to initiate mutation testing, the
extra work and expense to test for all three mutations is
relatively small given that she will have already gone
through counselling and provided a blood sample from
which DNA had been extracted. However, it would be of
interest to consider the specific mutations alone, given
that they might be associated with different risks of breast
and ovarian cancer [2]. We have also not included third-
degree relatives or breast cancer in male relatives, even
though these might be predictive, because these features
were either not evident or not recorded in our data sets.
That might explain some of the apparent underestimation
of mutation carriers in women with λ scores of less than
–2. For the same reason we have not addressed the issue
of whether, if there are multiple cancers in the family
(including the proband), they are in genetically related
women (that is, on the ‘same side of the family’). It would
seem prudent to base the prediction of mutation status on
cancers in genetically related women only.
Bilateral breast cancer is a difficult feature to model
without knowing whether an affected woman has had uni-
lateral or bilateral mastectomy, and this is further compli-
cated when reference is to relatives. Nevertheless, our
data suggest that having breast cancer in two close rela-
tives is more predictive of mutation status than in having
one relative with two breast cancers herself.
The families that we have studied here are those who have
come forward from the Jewish community, and do not nec-
essarily have a strong cancer family history. In extrapolat-
ing to families with stronger histories, it could be important
to take into account whether affected relatives were on
the same side of the family.
It is tempting to consider whether this LAMBDA model
could be adapted to the estimation of BRCA1 and/or
BRCA2 mutation status in non-Ashkenazi women. It is
likely that the same predictors would apply, but given that
mutations in these genes are rarer the magnitudes of their
effects could be smaller (because they explain less familial
aggregation) and the baseline would be considerably
lower, perhaps by as much as 2 units on the LAMBDA
scale. Another future development would be to build into
the model for affected women those tumour characteristics
that recent studies have found to be associated with muta-
tions in BRCA1 and BRCA2 [26]. The combination of
these features might increase the sensitivity and specificity
of the LAMBDA model. It is also likely that this sort of mod-
elling could be useful in the setting of mutations in other
genes, such as the mismatch repair genes, and their rela-
tionship to a personal and family history of colorectal and
associated cancers, including measures of microsatellite
instability and immunohistochemistry status of tumours.
Conclusions
This model for predicting the probability that an Ashkenazi
Jewish woman carries a founder mutation in BRCA1 or
BRCA2 has been derived by using data from Ashkenazi
Jewish women living in Australia and the UK, as well as
data from a community study performed in Washington.
The risk factors and their predictive strengths seem to give
predictions consistent with pooled data from other Jewish
populations, specifically from North America and Israel.
The LAMBDA model is simple to use and might therefore
have wide clinical utility, because it seems to capture the
main features that predict mutation status.
It is important that future work both should compare the
performance of this LAMBDA model with other models for
predicting carrier status and should test the model in other
settings to assess its generality. Careful examination of the
model and fits, especially in subgroups, might lead to
modifications and improvements, especially in making this
concept suitable in a wider setting. With these aims, large
validation studies are being undertaken with the use of, for
example, the Northern American resources of the NIH-
funded Breast Cancer Family Registry.
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